Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey.
Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Headache. 2024 Mar;64(3):323-328. doi: 10.1111/head.14687. Epub 2024 Feb 22.
Glossopharyngeal neuralgia (GPN) is an unusual disorder causing severe, brief pain episodes in the areas supplied by the glossopharyngeal nerve. Initial treatment involves medications like carbamazepine, but if these are ineffective or cause side effects, interventional pain management techniques or surgery may be considered. Gamma Knife radiosurgery is becoming popular in managing GPN due to its lower risk of complications than surgical interventions like microvascular decompression or rhizotomy. In this retrospective case series, we examined the outcomes of Gamma Knife radiosurgery in eight patients with GPN. The decision to utilize Gamma Knife radiosurgery was made following specific criteria, including failed surgical interventions, patient preference against surgery, or contraindications to surgical procedures. Patients were administered radiation doses within the range of 80 to 90 Gy, targeting either the cisternal glossopharyngeal nerve or glossopharyngeal meatus of the jugular foramen. Evaluations were conducted before the Gamma Knife radiosurgery; at 3, 6, and 12 months after Gamma Knife radiosurgery; and annually thereafter. Pain severity was assessed using the modified Barrow Neurological Institute scale grades, with patients achieving grade I-IIIa considered to have a good treatment outcome and grade IV-V to have a poor treatment outcome. Pain control and absence of radiosurgery-related complications were primary endpoints. The median age of the patients was 46.5 years, varying from 8 to 72 years. The median duration of pain was 32 months (range, 12-120 months). All patients, except one, were on polydrug therapy. All cases exhibited preoperative grade V pain. The median follow-up duration after Gamma Knife radiosurgery was 54.5 months, varying from 14 to 90 months. The overall clinical assessments revealed a gradual neurological improvement, particularly within the first 8.5 weeks (range, 1-12 weeks). The immediate outcomes at 3 months revealed that all patients (8/8, 100%) experienced pain relief, with 25% (2/8) achieving a medication-free status (Grade I). Three patients (37%) experienced a recurrence during the follow-up and were managed with repeat Gamma Knife radiosurgery (n = 2) and radiofrequency rhizotomy (n = 1). At the last follow-up, 88% (7/8) of patients had pain relief (Grades I-IIIa), with three (37%) achieving a medication-free status (Grade I). No adverse events or neurological complications occurred. The patient who underwent radiofrequency rhizotomy continued to experience inadequately controlled pain despite medication (Grade IV). Gamma Knife radiosurgery is a non-invasive, efficacious treatment option for idiopathic GPN, offering short- and long-term relief without permanent complications.
舌咽神经痛(GPN)是一种罕见的疾病,会导致舌咽神经支配区域出现剧烈、短暂的疼痛发作。初始治疗包括卡马西平等药物,但如果这些药物无效或有副作用,可以考虑介入性疼痛管理技术或手术。由于伽玛刀放射外科手术的并发症风险低于微血管减压或神经根切断术等手术干预,因此在治疗 GPN 中越来越受欢迎。在这项回顾性病例系列研究中,我们检查了 8 例 GPN 患者接受伽玛刀放射外科手术的结果。决定使用伽玛刀放射外科手术的依据是具体标准,包括手术干预失败、患者对手术的偏好或手术禁忌证。患者接受的放射剂量在 80 至 90Gy 之间,针对的是颅底舌咽神经或颈静脉孔内的舌咽神经管。在伽玛刀放射外科手术前、手术后 3、6 和 12 个月以及此后每年进行评估。使用改良的巴罗神经研究所(Barrow Neurological Institute)分级来评估疼痛严重程度,达到 I-IIIa 级的患者被认为治疗效果良好,达到 IV-V 级的患者被认为治疗效果不佳。疼痛控制和无放射外科相关并发症是主要终点。患者的中位年龄为 46.5 岁,年龄范围为 8 至 72 岁。疼痛持续时间的中位数为 32 个月(范围为 12-120 个月)。除 1 例患者外,所有患者均接受多药物治疗。所有病例均表现为术前 V 级疼痛。伽玛刀放射外科手术后的中位随访时间为 54.5 个月,范围为 14 至 90 个月。总体临床评估显示神经功能逐渐改善,尤其是在最初的 8.5 周内(范围为 1-12 周)。术后 3 个月的即时结果显示,所有患者(8/8,100%)均缓解疼痛,25%(2/8)达到无药物状态(I 级)。3 例(37%)在随访期间复发,通过重复伽玛刀放射外科手术(n=2)和射频神经根切断术(n=1)进行管理。最后一次随访时,88%(7/8)的患者疼痛缓解(I-IIIa 级),37%(3/8)达到无药物状态(I 级)。无不良事件或神经并发症发生。接受射频神经根切断术的患者尽管服用了药物,但仍经历着疼痛控制不佳(IV 级)。伽玛刀放射外科手术是治疗特发性 GPN 的一种非侵入性、有效的治疗方法,可提供短期和长期缓解,且无永久性并发症。